<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162915</url>
  </required_header>
  <id_info>
    <org_study_id>2009-SCI-I</org_study_id>
    <nct_id>NCT01162915</nct_id>
  </id_info>
  <brief_title>Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury</brief_title>
  <official_title>Phase I, Single Center, Trial to Asses Safety and Tolerability of the Intrathecal Infusion of Ex-vivo Expanded Bone-marrow Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TCA Cellular Therapy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TCA Cellular Therapy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is based on preclinical (animal) studies showing that infusing bone marrow-derived&#xD;
      mesenchymal stem cells into the spinal fluid may contribute to improving neurologic function&#xD;
      in animal models with spinal cord injuries. Bone marrow (BM) contains several types of stem&#xD;
      cells that can produce functional cells. This includes cells that could help the healing&#xD;
      process of damaged neurologic tissue.&#xD;
&#xD;
      The primary objective of this study is to see if the injection of these cells, obtained from&#xD;
      your own bone marrow, is safe. A secondary objective is to evaluate if the treatment can&#xD;
      provide functional improvements (neuromuscular control and sensation) in the affected areas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, single-center trial to assess the safety and tolerability of an intrathecal&#xD;
      infusion (lumbar puncture) of autologous, ex vivo expanded bone marrow-derived mesenchymal&#xD;
      stem cells in a well-defined population of spinal cord injury patients.&#xD;
&#xD;
      Safety will be evaluated by neurological and non-neurological tests performed after&#xD;
      short-term (1 to 30 days) and long-term (2 to 12 months)follow-up evaluation periods after&#xD;
      cell infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Suspended due to lack of funding.&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <description>Phase I trial to assess safety of intrathecal infusion of autologous mesenchymal stem cell treatment in spinal cord injury.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Safety</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of autologous bone marrow-derived mesenchymal stem cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous bone marrow-derived mesenchymal stem cells.</intervention_name>
    <description>Intrathecal infusion of a single dose of ex vivo expanded MSC.</description>
    <arm_group_label>Safety</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 65&#xD;
&#xD;
          -  American Spinal Injury Association Impairment Scale A&#xD;
&#xD;
          -  Clinical evidence of lesions located below c-spine 5 (C-5)&#xD;
&#xD;
          -  Confirmation by MRI of injury level&#xD;
&#xD;
          -  Time between injury and enrollment greater than 2 weeks&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Platelet count greater than 100 Thousand/uL at screening&#xD;
&#xD;
          -  INR equal to or less than 1.5&#xD;
&#xD;
          -  Hematocrit less than 30% prior to bone marrow aspiration&#xD;
&#xD;
          -  Spinal cord injury within 60 months of screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anoxic brain injury&#xD;
&#xD;
          -  Inability to provide consent&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Neurological deficits attributed to lesions above C-5&#xD;
&#xD;
          -  Cerebro-vascular accidents with intracranial hemorrhage, acute brain injuries,&#xD;
             meningitis, hydrocephalus or other potential diseases where the pressure in the&#xD;
             cerebro spinal fluid is increased&#xD;
&#xD;
          -  Multiple sclerosis&#xD;
&#xD;
          -  Amyotrophic lateral sclerosis&#xD;
&#xD;
          -  Cerebral Palsy&#xD;
&#xD;
          -  Evidence of cancer over the last 3 years prior to enrollment&#xD;
&#xD;
          -  Immunosuppressive diseases&#xD;
&#xD;
          -  Platelet count lower than 100,000&#xD;
&#xD;
          -  White blood count greater than 15,000 unless the patient is on steroids&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Clinical or laboratory evidence of meningitis&#xD;
&#xD;
          -  Skin infection at the infusion site&#xD;
&#xD;
          -  Pregnant or planning to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>TCA Cellular Therapy, LLC</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tcacellulartherapy.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Cord Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

